

CLINICAL INVESTIGATOR TRAINING COURSE (CITC)

November 13-15, 2018

[Tommy Douglas Conference Center \(TDCC\)](#), 10000 New Hampshire Ave., Silver Spring, MD 20903

AGENDA

DESCRIPTION

The clinical investigator training course is designed for physicians, nurses, pharmacists and other healthcare professionals involved in clinical trials. Lectures presented by senior FDA experts as well as guest lecturers from industry and academia explore the scientific, regulatory and ethical aspects of clinical trials. They also include discussions of non-clinical, early clinical, and phase 3 studies, issues in the design and analysis of trials, safety and ethical considerations and FDA regulatory requirements related to the performance and evaluation of clinical studies. FDA lecturers are from the Center for Drug Evaluation and Research (CDER), Center for Devices and Radiological Health (CDRH), and the Center for Biologics Evaluation and Research (CBER).

LEARNING OBJECTIVES

After completion of this activity, the participant will be able to:

1. Explain the responsibilities of an investigator conducting a clinical trial.
2. Describe what to look for in drugs being studied in a clinical trial.
3. Describe the basic concepts of clinical trial design.
4. Review clinical data for sources of bias and error.

REFERENCES

1. Title 21, Chapter I, Subchapter A, parts 50 (protection of human subjects), 54 (financial disclosure by clinical investigators), and 56 (IRBs)
2. Title 21, Chapter I, Subchapter D, parts 300-499 (drugs for human use)
3. Title 21, Chapter I, Subchapter F, parts 600-680 (biologics)
4. Title 21, Chapter I, Subchapter H, parts 800-898 (medical devices)

TARGET AUDIENCE

This activity is intended for physicians, pharmacists, nurses, researchers and others who are responsible for the conduct of clinical trials.

CLINICAL INVESTIGATOR TRAINING COURSE (CITC)

November 13-15, 2018

[Tommy Douglas Conference Center \(TDCC\)](#), 10000 New Hampshire Ave., Silver Spring, MD 20903

AGENDA

TUESDAY, NOVEMBER 13 TH		
7:30 - 8:20	Registration Sign-in and Distribution of Course Material	
SESSION 1: TRIAL DESIGN		
8:20 - 8:30	Welcome and Introduction	Leonard Sacks, M.D. FDA, CDER
8:30 - 9:00	FDA Structure and Mandate	Leonard Sacks, M.D.
9:00 - 10:00	The Design of Clinical Trials Part I	Robert Temple, M.D. FDA, CDER
10:00 - 10:15	BREAK	
10:15 - 10:45	The Design of Clinical Trials Part II	Robert Temple, M.D. FDA, CDER
10:45 - 11:00	Discussion and Questions	Robert Temple, M.D.
11:00 - 11:30	Clinical Outcomes Assessments	Elektra Papadopoulos, M.D. FDA, CDER
11:30 - 12:00	Electronic Technologies in Clinical Trials and clinicaltrials.gov	Leonard Sacks, M.D. Bridget Foltz, M.S. FDA, OC
12:00 - 12:15	Discussion and Questions	Bridget Foltz, M.S. Elektra Papadopoulos, M.D. Leonard Sacks, M.D.

CLINICAL INVESTIGATOR TRAINING COURSE (CITC)

November 13-15, 2018

[Tommy Douglas Conference Center \(TDCC\)](#), 10000 New Hampshire Ave., Silver Spring, MD 20903

AGENDA

12:15 - 1:15	LUNCH	
1:15 - 1:45	Issues in Clinical Trial Designs for Devices	Karen Ulisney, M.S.N., C.R.N.P FDA, CDRH
1:45 - 2:15	Issues in Clinical Trial Design for Companion Diagnostic Devices	Karen Bijwaard, M.S., RAC, MB(ASCP), CQA FDA, CDRH
2:15 - 2:45	Issues in Clinical Trial Design for Rare Diseases	Patroula Smpokou, M.D., FACMG FDA, CDER
2:45 - 3:00	Discussion and Questions	Karen Ulisney, M.S.N., C.R.N.P. Karen Bijwaard, M.S., RAC, MB(ASCP), CQA Patroula Smpokou, M.D., F.A.C.M.G.
3:00 - 3:15	BREAK	
SESSION 2: ETHICS AND HUMAN SUBJECT PROTECTION		
3:15 - 4:00	Informed Consent and Ethical Considerations in Clinical Trials	Jon Mark Hirshon M.D., Ph.D., M.P.H. University of Maryland
4:00- 4:45	Good Clinical Practice (GCP) Key Topics	Bridget Foltz, M.S. FDA, OC
4:45 - 5:00	Discussion and Questions	Jon Mark Hirshon M.D., Ph.D., M.P.H. Bridget Foltz, M.S.

CLINICAL INVESTIGATOR TRAINING COURSE (CITC)

November 13-15, 2018

[Tommy Douglas Conference Center](#), 10000 New Hampshire Ave., Silver Spring, MD 20903

AGENDA

WEDNESDAY, NOVEMBER 14		
8:15	Sign-in	
SESSION 3: TRIAL POPULATIONS AND SAFETY		
8:30 - 9:00	FDA Perspective on International Studies	Kassa Avalew, M.D., M.P.H. FDA, CDER
9:00 - 9:30	Clinical Discussion of Specific Populations	Su-Young Choi, Pharm.D., Ph.D. FDA, CDER
9:30 - 10:00	Safety Considerations in Phase I Trials	Joseph G. Toerner, M.D, M.P.H. FDA, CDER
10:00-10:30	Safety Assessment in Clinical Trials and Beyond	Yuliya Yasinskaya, M.D. FDA, CDER
10:30-10:45	Discussion and Questions	Kassa Avalew, M.D., M.P.H. Su-Young Choi, Pharm.D., Ph.D. Joseph G. Toerner, M.D, M.P.H. Yuliya Yasinskaya, M.D.
10:45-11:00	BREAK	

CLINICAL INVESTIGATOR TRAINING COURSE (CITC)

November 13-15, 2018

[Tommy Douglas Conference Center](#), 10000 New Hampshire Ave., Silver Spring, MD 20903

AGENDA

SESSION 4: INVESTIGATOR RESPONSIBILITIES		
11:00 - 11:30	Investigator Responsibilities-Regulation and Clinical Trials Part I	Cynthia Kleppinger, M.D. FDA, CDER
11:30 - 12:00	Investigator Responsibilities- Regulation and Clinical Trials Part II	Cynthia Kleppinger, M.D.
12:00 - 12:15	Discussion and Questions	Cynthia Kleppinger, M.D.
12:15 - 1:15	LUNCH	
SESSION 5: STATISTICAL CONSIDERATIONS		
1:15 - 2:00	The Analysis of Investigator Data, Sources of Bias and Error	Susan Ellenberg, Ph.D. University of Pennsylvania
SESSION 6: UNDERSTANDING THE INVESTIGATOR BROCHURE: NON-CLINICAL AND EARLY CLINICAL STUDIES		
2:00 - 2:30	CMC and the Investigator Brochure: Ensuring the Quality of a Drug is used in a Clinical Trial	Erika Englund FDA, CDER
2:30 - 3:15	Pharmacology/Toxicology in the Investigator Brochure	Brenda Gehrke, Ph.D. FDA, CDER

CLINICAL INVESTIGATOR TRAINING COURSE (CITC)

November 13-15, 2018

[Tommy Douglas Conference Center](#), 10000 New Hampshire Ave., Silver Spring, MD 20903

AGENDA

3:15 - 3:30	Discussion/Questions	Susan Ellenberg, Ph.D. Erika Englund Brenda Gehrke, Ph.D.
3:30 - 3:45	BREAK	
3:45 - 4:30	Clinical Pharmacology	Shirley Seo, M.D. FDA, CDER
4:30 - 5:00	Biosimilar Biological Products	Sue Lim, M.D. FDA, CDER
5:00 - 5:15	Discussion/ Questions	Shirley Seo, M.D. Sue Lim, M.D.

CLINICAL INVESTIGATOR TRAINING COURSE (CITC)

November 13-15, 2018

[Tommy Douglas Conference Center](#), 10000 New Hampshire Ave., Silver Spring, MD 20903

AGENDA

THURSDAY, NOVEMBER 15		
SESSION 7: INDs AND IDEs FROM START TO FINISH <i>Select a breakout session for drugs, devices, or biologics.</i>		
8:15	Sign-in	
Session 1A 8:30- 9:30	Center for Drug Evaluation and Research: How to Put together an IND Submission	<p>Judit Milstein, D.Sc. FDA, CDER</p> <p>Ei Thu Z. Lwin, Pharm.D. FDA, CDER</p>
Session 1B 8:30 - 9:30	Center for Biologics Evaluation and Research: Putting Together Your IND Application (CBER): CMC, Preclinical Testing and Clinical Trial Design Expectations to Ensure Safety for a First-in-Human Clinical Investigation	<p>Donald Fink, Ph.D. FDA, CBER</p> <p>Allen K. Wensky, Ph.D. FDA, CBER</p> <p>Rachel Witten, M.D. FDA, CBER</p>
Session 1C 8:30 - 9:30	Center for Devices and Radiological Health: How to Put together an IDE Submission: Safety and Effectiveness	<p>Jiping Chen, M.D., Ph.D., M.P.H. FDA, CDRH</p> <p>Joshua Chetta, Ph.D. FDA, CDRH</p> <p>Nadezda Radoja, Ph.D. FDA, CDRH</p>
9:30-9:45	BREAK	

CLINICAL INVESTIGATOR TRAINING COURSE (CITC)

November 13-15, 2018

[Tommy Douglas Conference Center](#), 10000 New Hampshire Ave., Silver Spring, MD 20903

AGENDA

Session 2A 9:45 - 10:45	Center for Drug Evaluation and Research Repeat of Session 1A	
Session 2B 9:45 - 10:45	Center for Biologics Evaluation and Research Repeat of Session 1B	
Session 2C 9:45 - 10:45	Center for Devices and Radiological Health Repeat of Session 1C	
10:45 - 11:00	BREAK <i>Breakout groups combine into main training room.</i>	
11:00 - 11:30	Clinical Investigator Site Inspections- What to Expect	Michelle Anantha, MSPAS, PA-C, RAC FDA, CDER
SESSION 8: PATIENT PERSPECTIVE		
11:30 - 12:00	Patient Perspective/ Engagement in Drug Development	Pat Furlong <i>Founding President & CEO</i> Parent Project Muscular Dystrophy
12:00 - 12:15	Discussion/Questions	Michelle Anantha, MSPAS, PA-C, RAC Pat Furlong
12:15-1:15	LUNCH	

CLINICAL INVESTIGATOR TRAINING COURSE (CITC)

November 13-15, 2018

[Tommy Douglas Conference Center](#), 10000 New Hampshire Ave., Silver Spring, MD 20903

AGENDA

SESSION 9		
SAFETY AND EFFICACY - SPECIAL TOPICS		
1:15 – 1:45	Phase I Development Oncology- Investigator's Perspective	Edward Sausville, M.D., Ph.D., F.A.C.P. University of Maryland
1:45 - 2:15	Hepatotoxicity	Mark Avigan, M.D. FDA, CDER
2:15 - 2:45	Special Cardiac Safety Concerns	Shari Targum, M.D. FDA, CDER
2:45 - 3:15	Human Genetics in Therapeutic Development and Clinical Trials	Alan R. Shuldiner, M.D. University of Maryland
3:15 - 3:30	Discussion, Explain Evaluation Process, Wrap-up and Adjourn	Mark Avigan Leonard Sacks M.D. Edward Sausville, M.D., Ph.D., F.A.C.P. Alan R. Shuldiner, M.D. Shari Targum, M.D.